MAM
VRTX icon

Milestone Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Milestone Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
2,714
+739
+37% +$328K 0.21% 105
2026
Q1 		$882K Sell
1,975
-1,164
-37% -$543K 0.16% 128
2025
Q4 		$1.42M Buy
3,139
+561
+22% +$242K 0.27% 73
2025
Q3 		$1.01M Buy
2,578
+30
+1% +$12.5K 0.19% 93
2025
Q2 		$1.13M Buy
+2,548
New +$1.17M 0.24% 77

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Milestone Asset Management's VRTX Position: Q2 2026 in Review

Milestone Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 37% in Q2 2026, buying an estimated $328K and bringing the position to 2,714 shares worth $1.35M. The position accounts for 0.21% of the portfolio, ranked #105.

Milestone Asset Management first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.42M in Q4 2025. 327 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Milestone Asset Management held 2,714 shares of Vertex Pharmaceuticals worth $1.35M as of Q2 2026.
  • Milestone Asset Management bought 739 Vertex Pharmaceuticals shares in Q2 2026, an estimated $328K.
  • Vertex Pharmaceuticals made up 0.21% of Milestone Asset Management's portfolio in Q2 2026, its #105 holding.
  • Milestone Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Milestone Asset Management's Vertex Pharmaceuticals position peaked at $1.42M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Milestone Asset Management's 13F filing for Q2 2026, filed 15 Jul 2026.